Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

French pharma company Servier and Oncodesign have selected a preclinical candidate from their Parkinson’s disease collaboration, which was first initiated in March 2019. ... Parkinson’s disease is an important part of our strategic focus, with a huge

Latest news

More from news
Approximately 1 fully matching, plus 321 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Yet, they cannot be the only relevant factors, since reduction of amyloid plaques from patients’ brains did not completely stop disease progression and this calls into focus the need to seriously ... An important prognostic marker is Apolipoprotein E4

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    would need to be developed so that the people most likely to benefit could be identified and treated early enough to delay the progression of this devastating disease. ... As in cancer, multiple drugs tackling different harmful processes involved in the

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    NIAID’s Adaptive COVID-19 Treatment Trial (ACTT-1) showed that remdesivir Standard of Care (SOC) significantly shortened time to recovery, provided greater clinical improvement and also reduced disease progression compared ... improvement and also

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    While there are medications that can address some of the risk factors for CKD, no cure currently exists, and few current therapies work directly to slow renal disease progression. ... At AstraZeneca, we are working to advance solutions across the full

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    Despite the significant anecdotal evidence, an initial study of Kaletra in China demonstrated some disappointing results; it did not seem to have any significant effect on disease progression. ... Infectious disease expert Lindsey R Braden and NEJM editor

More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...